Boehringer Ingelheim Pursuing M&A in China

Boehringer Ingelheim Vetmedica GmbH (Boehringer) will follow a two-pronged approach to China’s market. It will seek to expand its prescription drug business by introducing more of its global products in China, while it uses M&A to increase its presence in the OTC sector. These transactions, expected to occur over the next three to five years, will include TCM-based companies. More details...